MedTrace Logo

Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital

NCT06141161 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-11-21

No results posted yet for this study

Summary

Asthma is a significant public health threat, affecting more than 300 million individuals globally. Asthma is classified as a non-communicable disease and leads to reduced quality of life, poor physical functioning and reduced emotional well-being. The impact of this disease can be widespread and extends beyond the person living with the disease, affecting the lives of their family members, carers, communities and the health care system (1).

Asthma is a variable chronic respiratory condition. It is characterized by symptoms of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness (AHR). The severity of asthma varies considerably, both between individuals and within individuals over time. Some people may have intermittent asthma and others may experience severe, potentially life-threatening disease (2, 3,4).

Conditions

  • Bronchial Asthma

Interventions

DRUG

corticosteroids

inhailed or oral corticosteroids

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06141161 on ClinicalTrials.gov